Mu Opioid Receptor (MOR) Neurons

Mu Opioid Receptor (MOR) Neurons

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Mu Opioid Receptor (MOR) Neurons</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Opioid Receptor Neurons</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Thalamus, Periaqueductal gray, Amygdala, NAcc, Cortex</td>
</tr>
<tr>
<td class="label">Receptor Type</td>
<td>MOR (OPRM1)</td>
</tr>
<tr>
<td class="label">Signaling</td>
<td>Gi-coupled, inhibitory</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>OPRM1 (chromosome 6q24-q25)</td>
</tr>
<tr>
<td class="label">Protein</td>
<td>Mu opioid receptor (MOR-1)</td>
</tr>
<tr>
<td class="label">Taxonomy</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology (CL)</td>
<td>[CL:0000197](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000197)</td>
</tr>
</table>

Introduction

Mu Opioid Receptor (Mor) Neurons is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

...

Mu Opioid Receptor (MOR) Neurons

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Mu Opioid Receptor (MOR) Neurons</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Opioid Receptor Neurons</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Thalamus, Periaqueductal gray, Amygdala, NAcc, Cortex</td>
</tr>
<tr>
<td class="label">Receptor Type</td>
<td>MOR (OPRM1)</td>
</tr>
<tr>
<td class="label">Signaling</td>
<td>Gi-coupled, inhibitory</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>OPRM1 (chromosome 6q24-q25)</td>
</tr>
<tr>
<td class="label">Protein</td>
<td>Mu opioid receptor (MOR-1)</td>
</tr>
<tr>
<td class="label">Taxonomy</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology (CL)</td>
<td>[CL:0000197](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000197)</td>
</tr>
</table>

Introduction

Mu Opioid Receptor (Mor) Neurons is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Mu opioid receptors (MOR, encoded by OPRM1) are inhibitory Gi/o-coupled G protein-coupled receptors widely distributed throughout the central nervous system. These receptors are the primary target for endogenous opioid peptides (endorphins, enkephalins) and exogenous opioid analgesics (morphine, heroin, fentanyl). MOR neurons play critical roles in pain modulation, reward processing, autonomic function, immune modulation, and neuroendocrine regulation. Dysregulation of MOR signaling is implicated in chronic pain, opioid use disorder, Parkinson's disease, Alzheimer's disease, and various neuropsychiatric conditions. [@mandel2020]

Overview

Multi-Taxonomy Classification

Taxonomy Database Cross-References

External Database Links

• [Cell Ontology (CL:0000197)](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000197)
• [OBO Foundry (CL:0000197)](http://purl.obolibrary.org/obo/CL_0000197)
• [Allen Brain Cell Atlas](https://portal.brain-map.org/atlases-and-data/bkp/abc-atlas)
• [CellxGene Census](https://cellxgene.cziscience.com/)
• [Human Cell Atlas](https://www.humancellatlas.org/)

Molecular Properties

Receptor Structure

The mu opioid receptor is a 7-transmembrane domain GPCR belonging to the opioid receptor family (μ, δ, κ, NOP). MOR exhibits the highest affinity for endogenous β-endorphin and enkephalins, as well as classical opioid analgesics.

• Family: Opioid receptors (μ, δ, κ, NOP)
• G protein: Gi/o (inhibitory)
• Second messenger: cAMP decreases, K+ channels open, Ca2+ channels close
• Isoforms: Multiple splice variants (MOR-1A, MOR-1B, etc.) with distinct distributions
• Structure: Class A GPCR with distinct opioid-binding pocket

Signaling Pathways

MOR activation triggers multiple inhibitory signaling cascades:

Adenylyl cyclase inhibition: Gi/o protein inhibition of adenylyl cyclase reduces cAMP production, counteracting excitatory signaling

potassium channel activation: Activation of GIRK (G protein-activated inward rectifier K+) channels hyperpolarizes neurons

Voltage-gated calcium channel inhibition: N-type VGCC inhibition reduces neurotransmitter release

β-arrestin pathways: β-arrestin recruitment leads to receptor internalization and can mediate distinct signaling cascades

Distribution in the Brain

MOR is extensively distributed throughout the neuraxis:

• Periaqueductal gray (PAG): High density, primary site of opioid analgesia
• Rostral ventral medulla (RVM): Descending pain modulation
• Thalamus: Medial and intralaminar nuclei, pain perception
• Amygdala: Central nucleus, emotional and fear responses
• Hippocampus: CA1-3 regions, memory and spatial processing
• Cortex: Layer 5 pyramidal neurons, higher-order processing
• Nucleus accumbens: Shell region, reward and motivation
• Ventral tegmental area (VTA): GABAergic interneurons, reward circuitry
• Hypothalamus: Preoptic area and arcuate nucleus, neuroendocrine control
• Spinal cord: Substantia gelatinosa (lamina II), pain transmission

Physiological Functions

Pain Modulation

MOR neurons are central to endogenous and exogenous opioid analgesia:

• Supraspinal analgesia: MOR in PAG and RVM activate descending inhibitory pathways to the spinal cord
• Spinal analgesia: MOR on primary afferent terminals and spinal interneurons inhibit nociceptive transmission
• Peripheral analgesia: MOR on peripheral sensory nerve endings
• Emotional component: MOR in amygdala modulates affective dimension of pain

The analgesia mechanism involves:

Hyperpolarization of pain-transmitting neurons

Reduced glutamate release from primary afferents

Enhanced GABAergic inhibition of pain pathways

Activation of descending inhibitory serotonergic and noradrenergic pathways [1](https://doi.org/10.1016/j.pharmthera.2019.107418)

Reward and Addiction

MOR in the mesolimbic dopamine system is crucial for opioid reward and addiction:

• VTA GABAergic interneurons: MOR inhibition disinhibits VTA dopamine neurons
• Nucleus accumbens shell: MOR on medium spiny neurons modulates reward processing
• Conditioned place preference: MOR activation is sufficient to produce place preference
• Withdrawal and dependence: Chronic MOR activation leads to compensatory upregulation of adenylyl cyclase (adenylyl cyclase superactivation)

Autonomic and Neuroendocrine Regulation

• Respiratory control: MOR in medulla oblongata regulates breathing; MOR activation causes respiratory depression (major cause of opioid overdose death)
• Miosis: MOR in Edinger-Westphal nucleus constricts pupils
• Gastrointestinal motility: MOR in enteric nervous system inhibits GI transit (constipation)
• HPA axis: MOR modulates hypothalamic CRH and pituitary ACTH release
• Thermoregulation: MOR affects body temperature regulation

Immune Modulation

• Neuroimmune signaling: MOR on glial cells modulates neuroinflammation
• Peripheral immunity: MOR affects lymphocyte function and cytokine production
• Neuroprotection: MOR activation can have neuroprotective effects through anti-inflammatory mechanisms

Disease Involvement

Parkinson's Disease

• Motor complications: MOR dysregulation in basal ganglia contributes to levodopa-induced dyskinesias
• Pain: MOR agonists can treat Parkinson's-related pain syndromes
• Non-motor symptoms: Dysregulation of MOR in non-motor circuits contributes to depression and anxiety
• Neuroinflammation: MOR on microglia modulates neuroinflammatory responses in PD [2](https://doi.org/10.1016/j.parkreldis.2020.07.015)

Alzheimer's Disease

• Memory effects: Hippocampal MOR modulate memory consolidation; chronic opioid use associated with cognitive impairment
• Cholinergic interaction: MOR activation can inhibit basal forebrain cholinergic neurons
• Amyloid interaction: Evidence for cross-talk between MOR signaling and amyloid pathology
• Pain and behavior: AD patients often require opioid analgesics; careful dosing required due to sensitivity [3](https://doi.org/10.1016/j.neurobiolaging.2020.04.019)

Opioid Use Disorder

• Addiction neurobiology: MOR is central to opioid reinforcement and dependence
• Tolerance: Cellular and molecular mechanisms include receptor desensitization, internalization, and adenylyl cyclase superactivation
• Withdrawal: Physical dependence mediated by adaptations in MOR signaling pathways
• Treatment: Methadone, buprenorphine, and naltrexone target MOR

Chronic Pain

• Opioid analgesia: MOR agonists remain most effective analgesics for severe pain
• Opioid-induced hyperalgesia: Paradoxical increase in pain sensitivity with chronic opioid use
• Peripheral vs. central analgesia: Differential contributions of peripheral and central MOR

Therapeutic Implications

Opioid Analgesics

• Morphine: Classic MOR agonist, gold standard for severe pain
• Fentanyl: High potency synthetic opioid, rapid onset
• Oxycodone, Hydromorphone: Semi-synthetic opioids
• Tramadol, Tapentadol: Weaker MOR agonists with additional mechanisms

Addiction Treatment

• Methadone: Full MOR agonist, long half-life, prevents withdrawal
• Buprenorphine: Partial MOR agonist with ceiling effect for respiratory depression
• Naltrexone: MOR antagonist, blocks opioid effects

Novel Therapeutic Approaches

• Biased agonists: G protein-biased MOR agonists (e.g., oliceridine) provide analgesia with reduced respiratory depression
• Peripherally-restricted agonists: Reduce central side effects
• Combination therapies: MOR agonists with non-opioid analgesics
• Gene therapy: Viral vector-mediated MOR modulation

Side Effects and Safety

• Respiratory depression: Most dangerous side effect, naloxone reversible
• Constipation: Most common, requires prophylaxis
• Sedation and cognitive effects: Particularly problematic in elderly
• Endocrine effects: Hypogonadism, adrenal insufficiency
• Tolerance and dependence: Limits long-term use

Research Directions

• Structural biology: Cryo-EM structures of MOR bound to various ligands
• Biased signaling: Understanding G protein vs. β-arrestin pathways
• Genetic variants: OPRM1 polymorphisms and analgesic response
• Non-addictive analgesics: Developing MOR-targeted analgesics without addiction potential
• PET imaging: New MOR ligands for research and clinical use

See Also

• [Opioid Neurotransmission
• Opioid Receptors
• [Delta Opioid Receptor Neurons](/cell-types/delta-opioid-receptor-neurons)
• [Kappa Opioid Receptor Neurons](/cell-types/kappa-opioid-receptor-neurons)
• [Periaqueductal Gray Neurons](/cell-types/periaqueductal-gray-neurons)
• Nucleus Accumbens Neurons

](/cell-types/opioid-neurotransmission
--opioid-receptors
--delta-opioid-receptor-neurons
--kappa-opioid-receptor-neurons
--periaqueductal-gray-neurons
--nucleus-accumbens-neurons)## External Links

• [Wikipedia: Mu opioid receptor](https://en.wikipedia.org/wiki/Mu_opioid_receptor)
• [IUPHAR/BPS Guide to Pharmacology: μ-opioid receptor](https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=319)
• [UniProt: OPRM1](https://www.uniprot.org/uniprot/P35372)

Background

The study of Mu Opioid Receptor (Mor) Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Pathway Diagram

The following diagram shows the key molecular relationships involving Mu Opioid Receptor (MOR) Neurons discovered through SciDEX knowledge graph analysis: